Neurocognitive & Dementia Genetics Panel
The Neurocognitive and Neurological Panel analyzes established genetic markers linked to late-onset memory impairment, cerebral amyloid deposition, and neurodegenerative conditions. Early identification allows healthcare providers to implement evidence-based neuroprotective interventions, vascular health monitoring, and personalized cognitive wellness plans years before clinical symptoms progress.
Check If You Qualify
Takes under 2 minutes • 100% Covered under Medicare Part B
Who Should Consider This Screening?
Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:
Biomarkers & Genes Evaluated in this Panel
Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.
| Gene Symbol / Name | Clinical Significance | Actionable Impact |
|---|---|---|
| APOE (e2 / e3 / e4 alleles)Apolipoprotein E Allelic Genotyping | The strongest established genetic susceptibility marker for late-onset sporadic cognitive decline. | Informs early lifestyle, vascular risk management, sleep hygiene, and specialized neurological baseline testing. |
| PSEN1 & PSEN2Presenilin 1 & 2 Catalytic Subunits | Regulates amyloid precursor protein (APP) processing and gamma-secretase activity. | Distinguishes early-onset familial variants from age-related memory vulnerabilities. |
| MAPT & GRNMicrotubule-Associated Protein Tau & Progranulin | Associated with frontotemporal lobar degeneration and tauopathy pathways. | Assists clinicians in differential diagnosis of atypical neurological and movement symptoms. |
Sample Report & Diagnostic Action Plan
Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.
APOE Genotype: e3/e4 (Heterozygous for the e4 susceptibility allele).
Recommend annual Montreal Cognitive Assessment (MoCA), intensive management of cardiovascular lipids/blood pressure, and antioxidant-rich Mediterranean dietary protocol.
Medicare Part B Coverage Guidelines
Understand how federal CMS medical necessity guidelines apply to this specific diagnostic screening:
Medicare Part B covers diagnostic neurological screening when ordered by a licensed physician in the context of cognitive evaluations, memory loss symptoms, or hereditary neurodegenerative family history.
Ready to Check Your Eligibility for Neurocognitive & Dementia Genetics Panel?
Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed